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ABSTRACT
Although conventional therapies for acute myeloid leukemia (AML) and diffuse 
large B-cell lymphoma (DLBCL) are effective in inducing remission, many patients 
relapse upon treatment. Hence, there is an urgent need for novel therapies. PIM 
kinases are often overexpressed in AML and DLBCL and are therefore an attractive 
therapeutic target. However, in vitro experiments have demonstrated that intrinsic 
resistance to PIM inhibition is common. It is therefore likely that only a minority of 
patients will benefit from single agent PIM inhibitor treatment. In this study, we 
performed an shRNA-based genetic screen to identify kinases whose suppression is 
synergistic with PIM inhibition. Here, we report that suppression of p38α (MAPK14) is 
synthetic lethal with the PIM kinase inhibitor AZD1208. PIM inhibition elevates reactive 
oxygen species (ROS) levels, which subsequently activates p38α and downstream 
AKT/mTOR signaling. We found that p38α inhibitors sensitize hematological tumor 
cell lines to AZD1208 treatment in vitro and in vivo. These results were validated in 
ex vivo patient-derived AML cells. Our findings provide mechanistic and translational 
evidence supporting the rationale to test a combination of p38α and PIM inhibitors 
in clinical trials for AML and DLBCL.
INTRODUCTION
Cancer cells are highly dependent on oncogenic 
signaling, making targeted agents that specifically 
inhibit these pathways an attractive treatment option. 
Unfortunately, the majority of inhibitors demonstrate a 
modest or complete lack of response when used as a single 
agent, due to rapid resistance caused by redundancy or 
feedback signaling [1]. As a result, many potentially useful 
agents will not make it through early phase clinical trials. 
It is therefore essential, even before the start of clinical 
studies, to identify powerful drug combinations that 
prevent therapy resistance. One such promising class of 
drugs currently being evaluated in phase I clinical trials are 
the PIM kinase inhibitors (NCT01588548, NCT01489722, 
NCT02078609, and NCT02160951). 
PIM kinases (PIM1, -2, and -3) are a family of 
short-lived, constitutively active serine/threonine kinases 
which are often overexpressed in hematological tumors, 
including acute myeloid leukemia (AML), chronic 
myeloid leukemia (CML), the activated B-like (ABC) 
subtype of diffuse large B-cell lymphoma (DLBCL), and 
multiple myeloma (MM) [2-6]. The expression of PIM 
kinases is largely regulated via the JAK/STAT pathway 
on a transcriptional level, since PIM kinases have a 
short half-life [7-9]. Approximately 30 percent of AML 
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patients harbor the FLT3 internal tandem duplication 
(FLT-ITD), which results in high JAK/STAT signaling and 
consequently PIM overexpression [10-12]. Furthermore, 
the transcription factors NF-κB and HOXA9 can regulate 
PIM expression and are often highly active in AML [13-
15].
PIM kinases are highly redundant and regulate the 
activity of substrates involved in translation, survival, 
cell cycle, and MYC-dependent transcription. Several 
substrates overlap with AKT/mTOR signaling, including 
PRAS40 [16], TSC2 [5], 4EBP1 [17], and EIF4B [18-
20]. Furthermore, PIM kinases can suppress apoptosis by 
phosphorylating BCL2-associated agonist of cell death 
(BAD) [21-23], resulting in the dissociation of BCL-
2 and BCL-XL. Other substrates include MYC, and the 
cell cycle regulating proteins p21 (CDKN1A) [24, 25], 
p27KIP1 (CDKN1B) [26], CDC25A [27], and CDC25C 
[27].
PIM kinases contain a unique ATP-binding pocket, 
which has resulted in the development of highly selective 
pan-PIM inhibitors such as AZD1208 [6, 28, 29]. 
However, in vitro experiments have already demonstrated 
intrinsic resistance to PIM inhibitors, which will likely 
undermine the success of these compounds in the clinic [6, 
30]. Indeed, initial phase I clinical trial results demonstrate 
no benefit from the use of AZD1208 in advanced solid 
tumors and malignant lymphoma (NCT01588548). In 
this study, we used an shRNA-based screening approach 
to identify kinases whose suppression is synergistic with 
PIM inhibition. 
RESULTS
An shRNA screen identifies p38α loss to enhance 
the efficacy AZD1208
To study the effect of PIM inhibition on AML cell 
growth, we treated 6 cell lines expressing PIM1 or PIM2 
for 5 days with AZD1208 and measured viability (Figure 
1A and S1A). Whereas 4 out of 6 cell lines were sensitive 
to treatment (IC50 < 0.5 μM), 2 cell lines (OCI-M1 and 
OCI-M2) were intrinsically resistant to AZD1208 (IC50 > 
10 μM). To gain insights into the biochemical differences 
underlying these responses, we treated 2 sensitive and 
2 resistant cell lines with AZD1208 and analyzed the 
major targets of PIM kinases (Figure 1B). We observed 
a complete blockade of BAD phosphorylation in all 
cell lines, indicating that AZD1208 inhibited PIM 
kinase activity. In contrast, only the sensitive cell lines 
demonstrated reduced phosphorylation of PRAS40, S6, 
and 4EBP1. Since these targets are also regulated by 
mTOR, resistance might occur through sustained mTOR 
signaling upon PIM inhibition.
To identify genes whose suppression confers 
sensitivity to AZD1208, we performed a loss of function 
genetic screen using a kinome library consisting of 
3530 short hairpins RNAs (shRNA) in lentiviral vectors 
targeting 535 kinases and kinase-related genes [31]. We 
infected OCI-M1 cells with the library and cultured cells 
in the presence or absence of 2 μM AZD1208 (Figure 1C). 
After 16 days, we isolated genomic DNA, recovered the 
shRNA inserts by PCR amplification, and performed next 
generation sequencing to quantify the shRNA sequences. 
The individual replicates highly correlated and clustered 
together according to the absence or presence of drug 
(Figure S1B-S1C). To exclude false positives, we only 
called genes a hit when at least 2 shRNAs - present with 
more than 300 reads in the untreated population - gave a 
minimal fold-reduction of 2. Furthermore, these shRNAs 
should not be depleted from the untreated population 
compared to the T0 sample - indicative of a straight lethal 
effect. Two hairpins targeting mitogen activated protein 
kinase 14 (MAPK14 or p38α) fulfilled these criteria, 
suggesting that p38α loss sensitizes AML cells to PIM 
inhibition (Figure 1D). We validated the shRNAs targeting 
p38α by treating drug resistant parental OCI-M1 cells or 
p38α knockdown cells with AZD1208 in a 5-day viability 
assay (Figure 1E). The level of knockdown was assessed 
on protein and mRNA level (Figure 1F-1G).
Pharmacological inhibition of p38α restores 
sensitivity to AZD1208 through inhibition of 
mTOR signaling
To assess whether AZD1208 synergizes with p38 
inhibitors, we treated resistant AML (OCI-M1, OCI-M2), 
DLBCL (U2932, TMD8), and chronic myeloid leukemia 
(CML) (K562) cell lines with the combination of 
AZD1208 and the p38 inhibitors SB202190 or SCIO-469 
(the latter is in phase II clinical trial for multiple myeloma: 
NCT00095680) (Figure 2A-2E and Figure S2A-S2C). 
Single drug treatment modestly inhibited viability, 
whereas dual inhibition synergistically suppressed growth. 
To determine the level of synergy, we used a previously 
described method that calculates additive effects (based 
on the Loewe smodel) and subtracts these values from the 
experimental values resulting in a synergy score (Figure 
S2D) [32]. We furthermore calculated combination indices 
- which is a widely accepted method to calculate synergy. 
A high synergy score and vice versa a low combination 
index indicate strong synergy. To determine the 
significance of our findings, we also treated cells with self-
self inhibitor combinations, which theoretically should 
result in a synergy score of 0 and a combination index 
of 1. As expected, combined treatment of AZD1208 and 
either SB202190 or SCIO-469 resulted in high synergy 
scores and low combination indices (Figure 2F and Figure 
S2E). 
Since AZD1208 treatment did not suppress mTOR 
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Figure 1: An shRNA screen identifies p38α loss to be synthetic lethal with PIM inhibitor treatment. A. Short-term viability 
assay of a panel of AML cell lines. Cells were treated for 5 days with increasing concentrations of AZD1208 and viability was measured 
using CellTiter-Blue (n = 3). B. AZD1208-resistant AML cell lines demonstrate sustained mTOR signaling upon treatment. Cells were 
treated for 4, 24, and 48 hours with 1 μM AZD1208 followed by western blot analysis (n = 3). C. Schematic outline of the synthetic lethality 
screen. OCI-M1 cells were infected with a lentiviral kinome shRNA library and cultured in the presence or absence of 2 μM AZD1208 
for 16 days in replicates. shRNA barcodes were subsequently recovered by PCR and analyzed by next generation sequencing. D. The 
shRNA screen identifies p38α loss to be synthetic lethal with AZD1208. The x-axis depicts the average number of sequencing reads in the 
untreated sample (intensity). The y-axis depicts the fold change in abundance of shRNAs in the treated versus untreated population. Two 
shRNAs ( > 300 reads) targeting p38α were depleted in the treated population with a fold change of > 2. E. p38α knock down enhances 
AZD1208 response. OCI-M1 cells were infected with two shRNAs targeting p38α - pLKO serves as the control - and treated for 5 days with 
AZD1208. Cell viability was measured using CellTiter-Blue (n = 3). F.-G. Knock down of p38α was assessed on RNA and protein level.
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signaling in resistant cell lines, we analyzed this pathway 
upon dual PIM/p38 inhibition. Combined treatment 
reduced p-PRAS40, p-S6, and p-4EBP1 levels in all 
cell lines after 48 hours (Figure 2G and Figure S2F). 
In addition, both AZD1208-resistant and sensitive cell 
lines were sensitive to mono-treatment with the mTOR 
inhibitor AZD8055, suggesting that the growth inhibitory 
effect of AZD1208 is mainly via its effects on mTOR 
signaling (Figure S2G). Together, these data suggest that 
p38 inhibition can block PIM inhibitor resistance through 
suppression of mTOR signaling. 
PIM inhibition activates p38/AKT signaling
To gain further mechanical insights in the synergy 
between p38 and PIM inhibition, we treated AML 
cell lines with AZD1208 and assessed the activity of 
p38 signaling (Figure 3A). PIM inhibition elevated 
phosphorylation levels of p38, MKK4 (upstream kinase), 
and MK2 (downstream target of p38). Milder activation 
of p38 and MK2 was observed in DLBCL and CML cell 
lines (Figure S3A). Several reports have described that 
MK2 - the downstream target of p38 - acts an activator of 
Figure 2: Pharmacological inhibition of p38 synergizes with AZD1208 through reduced mTOR signaling. A.-E. p38 
inhibitors enhance AZD1208 response. OCI-M1, OCI-M2, U2932, K562, and TMD8 cells were treated with increasing concentrations 
of AZD1208 (x-axis) and co-treated with the p38 inhibitor SB202190. Viability was measured after 5 days using CellTiter-Blue (n = 3). 
F. p38 inhibitors are synergistic with AZD1208. OCI-M1, OCI-M2, U2932, K562, and TMD8 cells were treated with 2-fold dilutions of 
AZD1208, SB202190, SCIO-469, or combinations for 5 days. Viability was assessed by CellTiter-Blue and used to calculate synergy 
scores. Self-self combination treatments were used as a baseline to determine significance (n = 3). P-values were calculated using a one-
way ANOVA and Dunnett’s test. p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****) G. Combined inhibition of PIM and 
p38 results in reduced AKT/mTOR signaling after 48 hours. OCI-M1 (2.105 cells/well in 6-well plate) and OCI-M2 (4.105 cells/well in 
6-well plate) cells were treated for 48 hours with 2 μM AZD1208, 20 μM SB202190, or the combination. Cell lysates were harvested and 
subjected to western blot analysis (n = 3).
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AKT by enhancing phosphorylation of serine 473 and 308, 
although the exact mechanism remains unclear [33-35]. 
Since resistant cell lines demonstrated sustained mTOR 
signaling upon AZD1208 treatment, we investigated 
whether PIM inhibition could activate mTOR via AKT. 
As depicted in Figure 3A, cell lines activate AKT upon 
AZD1208 treatment. Furthermore, combined treatment 
with AZD1208 and the AKT inhibitor MK2206 
synergistically blocked mTOR signaling and cell growth 
in a comparable manner to p38 inhibition (Figure 3B-3F 
and Figure S3B-S3D). 
AZD1208 treatment elevates ROS levels
We subsequently investigated the mechanism by 
which PIM inhibition results in p38 activation. A recent 
study by Song et al. demonstrated that PIM knockout 
results in elevated reactive oxygen species (ROS) levels in 
mouse embryonic fibroblasts (MEFs) [36]. Since ROS is a 
known activator of p38 signaling [37], we measured total 
ROS and mitochondrial superoxide levels upon AZD1208 
treatment in OCI-M1 and OCI-M2 cell lines (Figure 4A-
4B). Interestingly, both ROS and superoxide levels were 
increased upon PIM inhibition, which could be reverted by 
treating cells with the ROS scavenger N-acetyl-cysteine 
(NAC). To validate that increased ROS levels can activate 
p38 in our cell lines, we treated OCI-M1 and OCI-M2 cell 
lines with ROS-inducing tert-butyl hydrogen peroxide 
(TBHP). As expected, induction of ROS levels results in 
rapid activation of p38 (Figure 4C). Furthermore, NAC 
prevented the activation of p38 signaling upon AZD1208 
treatment and blocked activation of S6/4EBP1 (Figure 
4D). These results suggest that PIM-inhibitor mediated 
upregulation of ROS might induce therapy resistance by 
activation of p38/AKT signaling.
Pharmacological inhibition of p38α enhances the 
efficacy of AZD1208 in primary AML cells and 
mouse xenografts
To translate our findings into a possible combination 
therapy in the clinic, we performed ex vivo drug testing 
assays with PIM-expressing AML patient-derived 
mononuclear cells obtained from the Erasmus Medical 
Center (Rotterdam, The Netherlands). Unfortunately, 
only 2 out of 7 available samples proliferated ex vivo, 
Figure 3: Activation of the p38 pathway upon PIM inhibition. A. The p38 signaling pathway is activated upon AZD1208 
treatment. OCI-M1 (2.105 cells/well in 6-well plate) and OCI-M2 (4.105 cells/well in 6-well plate) cells were treated with 2 μM AZD1208 for 
4, 24, and 48 hours. Cell lysates were harvested and subjected to western blot analysis (n = 3). B. Dual PIM/AKT inhibition synergistically 
inhibits mTOR signaling. OCI-M1 (2.105 cells/well in 6-well plate) and OCI-M2 (4.105 cells/well in 6-well plate) cells were treated for 
48 hours with 2 μM AZD1208, 2 μM MK2206, or the combination. Cell lysates were harvested and subjected to western blot analysis (n 
= 3). C.-E. AKT inhibition enhances AZD1208 response. OCI-M1, OCI-M2, and K562 cells were treated with increasing concentrations 
of AZD1208 (x-axis) and co-treated with the AKT inhibitor MK2206. Viability was measured after 5 days using CellTiter-Blue (n = 
3). F. MK2206 is synergistic with AZD1208. OCI-M1, OCI-M2, U2932, K562, and TMD8 cells were treated with 2-fold dilutions of 
AZD1208, MK2206, or the combination for 5 days. Viability was assessed by CellTiter-Blue and used to calculate synergy scores. Self-self 
combination treatments were used as a baseline to determine significance (n = 3). P-values were calculated using a one-way ANOVA and 
Dunnett’s test. p  ≤  0.01 (**) and p ≤ 0.0001 (****) 
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and were therefore considered for further experiments 
(Figure S4A). Since this particular drug combination 
mainly acts cytostatic rather than cytotoxic, we used 
the T0 value as a baseline (y-axis = ‘0’) for viability in 
the presented graphs rather than phenyl arsenic oxide 
(PAO). As a result, negative relative growth indicates a 
cytotoxic effect. Combined p38/PIM inhibitor treatment 
reduced proliferation in both AZD1208 resistant (#4576) 
and sensitive (#3186A) patient samples (Figure 5A-5B). 
Furthermore, dual p38/PIM inhibition prevented feedback 
activation of mTOR signaling in these cells (Figure 5C). 
To extend these findings, we tested an additional 7 
AML patient samples derived from the Helsinki University 
Central Hospital (Helsinki, Finland). Five of these samples 
proliferated ex vivo, and were therefore considered 
for further experiments (Figure S4B). Combined p38/
PIM inhibitor treatment reduced cell growth in 4 out of 
5 samples (#3853, #4361, # 4368, and #4374) (Figure 
5D-5G and Figure S4C). We subsequently performed 
a synergy analysis on all 6 samples (both Rotterdam 
and Helsinki data sets) (Figure 5H and Figure S4D). 
We observed high synergy scores and low combination 
indices in 4 of the 6 samples tested, suggesting that the 
combination of p38/PIM inhibitors is potentially beneficial 
for the treatment of AML. 
Our in vitro and ex vivo data suggest that PIM and 
p38 inhibition should also be synergistic when combined 
in vivo. To test this, we xenografted K562 cells into 
immunodeficient mice, treated animals with vehicle, 
AZD1208, SB202190, or the combination and assessed 
tumor growth (Figure 5I-5J). Single agent treatment 
did not inhibit tumor growth, whereas again only the 
combined treatment significantly reduced growth. 
DISCUSSION
Novel therapies are of utmost importance for the 
treatment of AML and DLBCL, since many patients 
relapse with conventional therapies [38, 39]. PIM kinases 
are often overexpressed and represent an interesting 
target due to the availability of highly selective inhibitors. 
Furthermore, mice deficient for all PIM kinases have no 
significant phenotype, which may indicate a favorable 
toxicity profile of specific PIM inhibitors in vivo [40]. 
However, similar to other targeted agents, resistance to 
PIM inhibitors occurs. This study provides a rationale to 
test a combination of p38 and PIM inhibitors in clinical 
trials. We demonstrated that resistance to AZD1208 occurs 
through feedback activation of mTOR signaling, which is 
mediated by ROS, p38, and AKT (Figure 6). 
A recent study by Song et al. demonstrated elevated 
ROS levels upon PIM loss in mouse embryonic fibroblast 
cells [36]. Triple knock-out cells for PIM1, -2, and -3 were 
found to have decreased expression of genes involved in 
mitochondrial oxidative phosphorylation and lower levels 
of the ROS detoxifying genes superoxide dismutase 
Figure 4: PIM inhibition elevates ROS and mitochondrial superoxide levels. A.-B. OCI-M1 and OCI-M2 cells were treated 
for 48 hours with 5 μM AZD1208, 5 mM NAC, or the combination. Cells were incubated with CellRox or MitoSox - according to the 
manufacturer’s instructions - to stain for respectively ROS or mitochondrial superoxide and fluorescent intensity was measured by flow 
cytometry analysis (n = 3). C. Induction of ROS activates p38. OCI-M1 and OCI-M2 cells were treated for 0, 30, 60, 120, or 240 min 
with 400 μM TBHP. Cell lysates were harvested and subjected to western blot analysis (n = 3). D. ROS inhibition prevents PIM inhibitor-
mediated feedback activation of p38. OCI-M1 (2.105 cells/well in 6-well plate) and OCI-M2 (4.105 cells/well in 6-well plate) cells were 
treated for 48 hours with 2 μM AZD1208, 5 mM NAC, or the combination. Cell lysates were harvested and subjected to western blot 
analysis (n = 3)
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(SOD) 1, -2, and -3, glutathione peroxidase 4 (GPX4), 
and peroxiredoxin 3 (PRDX3). Another study by Lilli et 
al. describes that PIM expression delays mitochondrial 
dysfunction and ROS production upon IL-3 starvation 
in the murine myeloid cell line FDCP1 [41]. However, 
these findings were not the result of reduced SOD activity, 
but suggested to be through elevated expression of BCL-
2. This gene mainly plays a role in apoptosis, but also 
modulates oxidative phosphorylation and ROS levels 
[42, 43]. Interestingly, several groups have reported a 
synergistic interaction between PIM and BCL-2 inhibitors 
in hematological and solid tumors [44, 45]. 
Our results are in concordance with previous 
findings showing synergy between PIM and PI3K or 
Figure 5: Suppression  of p38 signaling restores sensitivity to PIM inhibition in primary AML cells and mouse 
xenografts. A.-B. Inhibition of p38 enhances AZD1208 response in primary AML cells. Patient cells were treated with increasing 
concentrations of AZD1208 (x-axis) and co-treated with 0.313 μM, 1.25 μM, or 5 μM SCIO-469. Growth was measured after 4 days using 
MTT. A day 0 measurement was used as a baseline value (y-axis = ‘0’) for growth. Negative relative growth indicates a cytotoxic effect (n 
= 2). C. Combined p38/PIM inhibition suppresses mTOR signaling. Primary AML cells were treated for 24 hours with 1 μM AZD1208, 10 
μM SCIO-469, or the combination. Cell lysates were harvested and subjected to western blot analysis. D.-G. Inhibition of p38 enhances 
AZD1208 response in a validation set of primary AML cells. Cells were treated with increasing concentrations of AZD1208 (x-axis) and 
co-treated with 0.3 μM, 1 μM, or 3 μM SCIO-469. Viability was measured after 72 hours using CellTiter-Glo. A day 0 measurement was 
used as a baseline value (y-axis = ‘0’) for growth. Negative relative growth indicates a cytotoxic effect (n = 2). H. SCIO-469 is synergistic 
with AZD1208. Primary AML cells were treated with 2-fold dilutions of AZD1208, SCIO-469, or the combination. Viability was assessed 
by CellTiter-Blue and used to calculate synergy scores. I. Dual PIM/p38 inhibition suppresses tumor growth in a xenograft model. K562 
cells (5.106) were subcutaneously implanted in Rag2−/−IL2γc−/− mice. Once tumors were established, animals were treated with vehicle, 
AZD1208 (30 mg/kg), SB202190 (5 mg/kg), or both drugs in combination. J. Mean tumor volume after 18 days treatment. Vehicle (n = 
11), AZD1208 (n = 12), SB202190 (n = 18), and combination (n = 14). P-values were calculated via one-way ANOVA and Dunnett’s test. 
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AKT inhibitors [30, 46]. However, these studies lacked 
insights in the mechanism underlying this synergistic 
interaction. Even more important, p38 inhibitors - which 
are in clinical trial for diseases such as rheumatoid 
arthritis, chronic obstructive pulmonary disease, and 
multiple myeloma - are likely less toxic than PI3K, AKT, 
and mTOR inhibitors and could therefore be preferred 
for combination therapies. Lower toxicity is particularly 
important since these targeted agents will likely be used 
on top of a chemotherapeutic backbone. To conclude, our 
findings suggest that AML patients might benefit from 
combined PIM and p38 inhibitor treatment.
MATERIALS AND METHODS
Cell culture and lentiviral transduction
OCI-M1 and OCI-M2 cells were cultured in Iscove’s 
Modified Dulbecco’s Medium (IMDM). EOL-1, CMK, 
MOLM-16, KG1a, TMD8, U2932, and K562 cells were 
cultured in Roswell Park Memorial Institute (RPMI) 1640. 
Medium was supplemented with 16% fetal calf serum 
(FCS), 1% glutamine, and 1% penicillin/streptomycin, 
and cells were grown at 37°C and 5% CO2. All cells were 
purchased at DSMZ, except TMD8, which was a kind gift 
from AstraZeneca, and K562, which was available within 
The Netherlands Cancer Institute. Cultured cells were 
routinely tested for mycoplasma infection.
PEI transfection of HEK293T cells was used to 
produce lentiviral supernatant. Target cells were seeded 
1 day before infection. Lentivirus was added to the 
medium in the presence of 5 µg/ml polybrene. Cells 
were selected for successful lentiviral integration using 
2 µg/ml puromycin. All lentiviral shRNA vectors were 
retrieved from the arrayed TRC human genome-wide 
shRNA collection. For individual knock down of genes, 
the following hairpins were used: 
p38α _TRCN0000000513_
CCATTTCAGTCCATCATTCAT; 
p38α_TRCN0000010052_
GTTCAGTTCCTTATCTACCAA;
Control infections were performed with the empty 
pLKO.1 vector. 
Synthetic lethality screen
A kinome library - consisting of 3530 short hairpins 
RNAs (shRNA) in lentiviral vectors, targeting 535 kinases 
and kinase-related genes - was used to infect OCI-M1 
cells with 1000-fold coverage. Cells were cultured in 
the absence or presence of drug in biological replicates 
for 16 days, followed by genomic DNA isolation using 
the DNAeasy Blood & Tissue Kit (Qiagen). shRNA 
cassettes were amplified using Phusion High Fidelity 
DNA polymerase (Thermo Scientific) by performing a 
2 step PCR amplification: (1) 98°C, 30 s; (2) 98°C, 10s; 
(3) 60°C, 20 s; (4) 72°C, 1 min; (5) to step 2, 16 cycles; 
(6) 72°C, 5 min; (7) 4°C. The abundance of each hairpin 
in the treated versus untreated pools was determined by 
Illumina next generation sequencing. 
Protein lysate preparation and western blot 
analysis
Cells were lysed using RIPA buffer containing 150 
mM NaCl, 50 mM Tris pH 8.0, 1% NP-40, 0.5% sodium 
deoxycholate and 0.1% SDS supplemented with protease 
Figure 6: Schematic overview of feedback activation of mTOR signaling upon PIM inhibition. AZD1208 treatment inhibits 
PIM activity; thereby elevating ROS levels which subsequently results in resistance through activation of p38, AKT, and mTOR signaling. 
Combined treatment of AZD1208 with either a p38 inhibitor (SCIO-469) or an AKT inhibitor (MK2206) prevents feedback activation 
of mTOR and restores PIM inhibitor sensitivity. Single mTOR inhibitor treatment (AZD8055) also prevents cell growth, indicating the 
dependency of hematopoietic tumor cells to this pathway.
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inhibitors (Complete, Roche) and phosphatase inhibitor 
cocktails II and III (Sigma). Sample buffer (60mM Tris 
pH 6.8, 5% glycerol, 1% SDS, 2% β-mercaptoethanol, 
0.02% bromophenol blue) was added, lysates were 
boiled for 10 minutes, and equal amounts of sample were 
subjected to SDS gel electrophoresis followed by western 
blotting. Primary antibody against HSP90 (SC-7947) was 
purchased from Santa Cruz. Antibodies against clPARP 
(#5625), PIM1 (#3247), PIM2 (#4730), p-AKT (#4060), 
AKT (#2920), p-PRAS40 (#2997), PRAS40 (#2610), p-S6 
(#2215), S6 (#2217), p-4EBP1 (#9456), 4EBP1 (#9452), 
p-BAD (#5284), BAD (#9292), p-p38 (#4511), p38 
(#8690), p-MK2 (#3007), MK2 (#3042), and p-MKK4 
(#9156) were from Cell Signaling. Secondary antibodies 
were obtained from Bio-Rad Laboratories. AZD1208 was 
a kind gift from AstraZeneca. SCIO-469 was purchased 
from Tocris, SB202190 from Selleckchem, and NAC from 
Sigma.
Quantitative RT-PCR
RNA was isolated using a Quick-RNA MiniPrep kit 
(Zymo Research, #R1055). Subsequent cDNA synthesis 
was performed using Maxima Universal First Strand 
cDNA Synthesis Kit (Thermo scientific, # K1661).
The 7500 Fast Real-Time PCR System from Applied 
Biosystems was used to measure mRNA levels. mRNA 
expression levels were normalized to expression of 
GAPDH. The following primer sequences were used in 
the SYBR Green master mix:
GAPDH_forward 
5’-AAGGTGAAGGTCGGAGTCAA-3’; 
GAPDH_reverse 
5’-AATGAAGGGGTCATTGATGG-3’; 
MAPK14_forward 
5’-TGGAGAGCTTCTTCACTGCC-3’; 
MAPK14_reverse 
5’-CGAGCGTTACCAGAACCTGT-3’
ROS measurement
Respectively 2.5.105 and 5.105 OCI-M1 and 
OCI-M2 cells per well were seeded in a 6-well plate in 2 
ml medium with or without 5 μM AZD1208. Following 
48 hours of culture, positive and negative control cells 
were treated according to the manufacturer’s instructions 
with 400 μM tert-butyl hydroperoxide (TBHP) and 5 mM 
N-acetyl cysteine (NAC). All samples were incubated 
for 1 hour with 500 nM CellROX green (ROS indicator, 
Molecular Probes) or 5 μM MitoSOX red (mitochondrial 
superoxide indicator, Molecular Probes) and subsequently 
analyzed by flow cytometry using 488 nm excitation for 
CellROX green and 510 nm excitation for MitoSOX red.
CellTiter-blue viability assay
Respectively 400 (OCI-M1), 500 (EOL-1), 1000 
(U2932, K562, CMK), 2500 (OCI-M2 and TMD8), or 
5000 (MOLM-16, KG1a) cells per well were seeded 
in a 96-well plate. After 24 hours, drugs were added to 
the medium in 2-fold serial dilutions using a HP Direct 
Digital Dispenser. After 5 days of culture CellTiter-Blue 
(Promega) was added. The conversion of resazurin into 
resorufin was measured by using an EnVision Multilabel 
Reader. Treatment with 10 μM phenyl arsenic oxide - 
resulting in complete cell death - was used as a baseline 
for viability.
Growth assays using primary AML ex vivo 
cultures
MTT assay (Rotterdam)
AML patient samples were obtained at diagnosis 
from bone marrow or peripheral blood of patients who 
had given informed consent according to institutional 
guidelines. Based on the g ene expression profile, primary 
AML samples expressing high PIM1 levels were selected 
for further experiments.  
Patient samples, previously frozen in liquid 
nitrogen in the presence of 10% DMSO, were thawed and 
suspended in RPMI 1640 supplemented with 20% FCS, 
1% insulin-transferrin-sodium selenite media supplement 
(Sigma-Aldrich), 1% L-glutamine, and 2% gentamicin. 
All samples contained 90% leukemic cells, determined 
morphologically on May-Grünwald-Giemsa (Merck)-
stained cytospins.
Cells were plated in 96-well plates (1.5.105 cells/
well) containing AZD1208 and/or SCIO-469. After 4 
days of culture, 3- [4,5-dimethylthiazol-2-yl]-2,5-diphenyl 
tetrazoliumbromide (MTT, 5 mg/ml, Sigma Aldrich) was 
added and the plates were incubated for an additional 6 
hours. During this incubation, the MTT tetrazolium salt is 
reduced to purple-blue formazan crystals by viable cells. 
Crystals were dissolved by acidified isopropanol (0.04N 
HCl-isopropyl alcohol) and the optical density (OD) was 
measured at 562nm (VersaMax, Molecular Devices). 
Cell viability for each sample was furthermore measured 
at 0 hours to monitor cell growth during the 96 hours of 
culture. 
It is important to note that a much larger number 
of cells derived from primary samples compared to cell 
lines is used per well for viability experiments. This 
results in a T0 read-out value that is much higher than PAO 
(whereas for cell line experiments these values are almost 
equal). Since this particular drug combination mainly acts 
cytostatic rather than cytotoxic, we used the T0 value as a 
baseline for viability in the presented graphs (y-axis = ‘0’). 
As a result, negative relative growth indicates a cytotoxic 
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effect.
CellTiter-glo assay (Helsinki)
Bone marrow samples obtained from 5 diagnostic 
(samples 4325, 4361, 4368, 4374 and 4401) and 2 
relapsed AML patients (samples 3853 and 370) with 
informed consent (approval # 239/13/03/00/2010, 
303/13/03/01/2011) were applied for the drug testing 
experiments. Leukemic blast counts of the bone marrow 
samples were between 25 and 90%. Previously frozen 
mononuclear cells derived from these samples, isolated 
by Ficoll density gradient (Ficoll-Paque PREMIUM; 
GE Healthcare), were thawed and suspended in RPMI 
1640 supplemented with 10% FCS, 12,5% human bone 
marrow stromal cell line HS-5 conditioned media [47], 
and 1% penicillin and streptomycin. 8000 cells per well 
were added in a 384 well plate containing AZD1208 and/
or SCIO-469. After 72 hours of culture, CellTiter-Glo 
(Promega) reagent was added to the wells to measure ATP 
levels - the amount of ATP is proportional to the number 
of viable cells present. Luminescence was measured using 
a PHERAstar plate reader (BMG Labtech). Cell viability 
for each sample was furthermore measured at 0 hours to 
monitor cell growth during the 72 hours of culture.
It is important to note that a much larger number 
of cells derived from primary samples compared to cell 
lines is used per well for viability experiments. This 
results in a T0 read-out value that is much higher than PAO 
(whereas for cell line experiments these values are almost 
equal). Since this particular drug combination mainly acts 
cytostatic rather than cytotoxic, we used the T0 value as a 
baseline for viability in the presented graphs (y-axis = ‘0’). 
As a result, negative relative growth indicates a cytotoxic 
effect.
Mouse xenografts
6- to 8-wk-old male Rag2−/−IL2γc−/− mice were 
housed in a specific pathogen-free facility in individually 
ventilated cages at the Animal Core Facilities of the Center 
for Applied Medical Research (University of Navarra). 
All mouse experiments were performed in compliance 
with protocols approved by the local Animal Ethics 
Committee, which conform to institutional and national 
regulatory standards on experimental animal usage. 
K562 cells (5.106) were subcutaneously implanted with 
matrigel (BD Bioscience) into the right flank of mice. 
When tumor size reached ~50 to 100 mm3, mice were 
randomly assigned and treated once daily with 30 mg/kg 
AZD1208 (AstraZeneca) by oral gavage and/or 5 mg/kg 
SB202190 (LC Laboratories) by intraperitoneal injection. 
Control group received vehicle (0.5% hydroxypropyl 
methylcellulose and 1% DMSO). All groups were 
composed of 11 to 18 mice. Tumor volume was measured 
three times per week with calipers and calculated as tumor 
volume = (length × width2) × 0.5.
Synergy score calculation
Cells were seeded in a 96-well plate (384-well 
plate for Helsinki samples) and treated with 5*5 pairs 
(5*9 for Helsinki samples) of serially diluted drugs for 
the indicated number of days. Cell viability was measured 
using CellTiter-Blue (cell lines), MTT (Rotterdam 
samples), or CellTiter-Glo (Helsinki samples).
 Measurements were normalized using ‘normalized 
percentage inhibition’ [48]. Values were transformed to 
values between 0 and 1 using the formula y = (x-p) /(n 
p) where x is the experimental value, n is the mean of the 
negative control, and p is the mean of the positive control 
(PAO). The effect level was calculated as: (1 - normalized 
value.) * 100 percent. A second matrix, the Loewe matrix, 
reflects the expected effect levels in case of additivity of 
the two drugs. The expected values were calculated using 
the formula of Loewe: D1/Dx1 + D2/Dx2 = 1 where D1 
and D2 are the dose of respectively drug 1 and drug 2 
in the combination. Dx1 is the single dose you would 
need from drug 1 in order to have the same effect x as 
the combination. Dx2 is this value for drug 2. Dx1 and 
Dx2 were determined using a fitted dose effect curve. The 
additive effect was determined with an heuristic method, 
in which for subsequent effect levels the outcome of the 
formula is calculated. The method starts with the highest 
effect of the two single drugs, for which the outcome of the 
formula will always be ≥ 1. The method continues until the 
value of 1 is crossed or the maximum of 100 is reached. 
The synergy score is calculated as the total of the positive 
values in the matrix divided by 100 [49]. Combination 
indices were calculated using the Chou-Talalay method 
[50]. Self-self synergy scores/ combination indices are the 
average score of all self-self drugs tested per cell line. 
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